Welcome to our dedicated page for NeOnc Technologies Holdings news (Ticker: NTHI), a resource for investors and traders seeking the latest updates and insights on NeOnc Technologies Holdings stock.
NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI) news coverage focuses on its progress as a clinical-stage life sciences and biopharmaceutical company developing central nervous system therapeutics designed to overcome the blood-brain barrier. News releases frequently highlight updates from Phase 1/2a and Phase 2a clinical trials of intranasal NEO100 in recurrent WHO Grade III/IV IDH1‑mutant astrocytoma and other high-grade gliomas, as well as regulatory and operational milestones across its CNS oncology pipeline.
Investors following NTHI news can expect detailed reports on radiographic response rates, progression-free survival and long-term survival outcomes from NEO100 studies, along with safety and tolerability findings associated with prolonged intranasal dosing. Additional news items describe the advancement of NEO212, a bio-conjugated chemotherapy candidate for primary and metastatic brain tumors, including U.S. Food and Drug Administration authorization to proceed with Phase IIa/IIb clinical development.
Company announcements also cover strategic partnerships and corporate developments, such as the establishment of the NuroMENA subsidiary in the United Arab Emirates, a Master Services Agreement with IROS (an M42-affiliated contract research organization), and share exchange or acquisition transactions disclosed in Form 8‑K filings. Updates on non-dilutive NIH STTR funding, intellectual property expansion, and NeOnc’s AI and 3D bioprinting initiatives for sonodynamic therapy research with NEO100 are also common themes.
By monitoring this NTHI news feed, readers can track NeOnc’s clinical data readouts, regulatory interactions, regional expansion efforts and financing-related disclosures as they are released through press announcements and SEC-referenced communications.
NeOnc Technologies (NASDAQ: NTHI) has secured board approval for a strategic $50 million partnership with Quazar Investment. The board unanimously approved the company's participation in the equity investment and MENA region expansion on June 30, 2025, marking the first of five required milestones.
The proposed structure includes a $25 per share pricing, with 70% of proceeds allocated to NeOnc common stock acquisition and 30% dedicated to clinical trials and infrastructure development in the UAE and MENA region. The company must complete remaining conditions within 120 days, including establishing NuroMENA and NuroCure in Abu Dhabi, executing licensing agreements for NEO100 and NEO212, and finalizing offering documents and business plans.
NeOnc Technologies Holdings (NASDAQ: NTHI), a clinical-stage biopharmaceutical company developing CNS cancer treatments, has been added to the Russell Microcap® Index following its 2025 annual reconstitution. This inclusion positions NTHI among select companies with market caps between $30 million and $3 billion, representing less than 3% of the U.S. equity market.
The company is currently advancing two Phase II clinical trials with its proprietary NEO100™ and NEO212™ therapeutics, both operating under FDA Fast-Track and IND status. NeOnc's drug development platform focuses on overcoming blood-brain barrier challenges, with patent protections extending to 2038. The company is also pursuing strategic expansion in the MENA region through a proposed partnership with Quazar in the GCC.
NeOnc Technologies (NASDAQ: NTHI) has signed a $50 million non-binding term sheet with Quazar Investment to establish NuroMENA Holdings Ltd and its subsidiary NuroCure in the UAE. The strategic partnership aims to expand NeOnc's clinical trials for brain cancer treatments into the GCC & MENA regions.
The deal includes a $50 million equity investment at $25 per share, with 70% allocated for NTHI common stock purchase and 30% for regional clinical trials and infrastructure. The partnership will leverage Cleveland Clinic Abu Dhabi's FDA-protocol trial facilities for NeOnc's drug candidates NEO100 and NEO212, targeting aggressive brain cancers DIPG and GBM.
The transaction, expected to close by July 10, 2025, is subject to several conditions including board approval (completed June 30, 2025), legal formation of entities, and execution of sub-license agreements within 120 days.
NeOnc Technologies Holdings (NASDAQ: NTHI) announced its global patent portfolio has reached 176 patents, strengthening its competitive position in oncology and neurology therapeutics. The portfolio includes 126 issued patents (29 U.S. and 97 international) and 50 pending patents (19 U.S. and 31 international).
The company's IP protection covers major pharmaceutical markets including the U.S., EU, China, Japan, Brazil, and Australia. Their lead programs (NEO100, NEO212, NEO214, and NEO400) are protected by extensive patent coverage. NEO100 is covered by eight U.S. patents expiring between 2031-2036, with potential extensions. The company also holds patents for blood-brain barrier permeability compounds with protections until 2039.
NeOnc Technologies Holdings (NASDAQ: NTHI) announced expected full enrollment completion for its Phase 2a clinical trial of NEO100-01 in September, with only six patients remaining to reach the 25-patient target. The trial investigates NEO100, a purified perillyl alcohol delivered intranasally for treating malignant gliomas, specifically IDH1 mutant Grade III and IV astrocytomas.
The trial's read-out data is anticipated in early 2026. NEO100-01 represents the first intranasal therapy of its kind for malignant gliomas, designed to bypass the blood-brain barrier through olfactory and trigeminal nerves. Phase 1 study data indicated extended survival post-recurrence with minimal side effects in IDH1 mutation patients. The FDA has granted both Orphan Drug Designation and Fast Track Status to NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced the appointment of Executive Chairman Amir Heshmatpour as the company's new President, while maintaining his role as Executive Chairman. This strategic move aims to accelerate the company's clinical initiatives, particularly focusing on central nervous system (CNS) cancers and disorders.
Heshmatpour brings over 25 years of executive experience, notably founding AFH Holdings & Advisory where he led IPO transactions worth over $1.5 billion and M&A deals exceeding $5 billion. His previous success includes founding Metrophone Telecommunications, which under his leadership completed 17 acquisitions and achieved annual revenues over $100 million.
In his expanded role, Heshmatpour will oversee daily operations while enabling CEO Dr. Thomas Chen to focus on advancing clinical trials, particularly patient enrollment for lead drug candidates NEO212 (TMZ bio-conjugate) and NEO100.
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced near-completion of Phase I enrollment for its brain cancer therapy NEO212. The trial's final cohort (Cohort 5) is approaching completion of the dosing protocol, with the study designed for 5 escalating cohorts of 3 patients each.
NEO212 is a novel bio-conjugated therapeutic combining temozolomide (TMZ), the current standard-of-care chemotherapy for malignant gliomas, with perillyl alcohol (POH), a natural anti-cancer compound. This innovative formulation aims to overcome TMZ's limitations, including rapid bloodstream degradation, bone marrow suppression, and effectiveness in tumors with active MGMT DNA-repair enzyme expression.
The drug is engineered as a stable, orally bioavailable molecule, maintaining effectiveness in both MGMT-positive and MGMT-negative gliomas, potentially offering improved tumor targeting with reduced systemic side effects.
NeOnc Technologies Holdings (NASDAQ: NTHI) has received Rare Pediatric Disease Designation (RPDD) from the FDA for their drug NEO100™ (perillyl alcohol) in treating pediatric-type diffuse high-grade gliomas. This aggressive form of brain cancer primarily affects children from birth to 18 years.
The designation qualifies NTHI for a potential Rare Pediatric Disease Priority Review Voucher (PRV) upon marketing approval of NEO100. These vouchers, which can be sold or transferred, hold significant strategic and financial value in the current market.
The FDA's decision was based on the disease meeting the statutory definition of a 'rare disease or condition.' The company is advancing NEO100 through clinical trials while collaborating with healthcare providers and patient advocacy groups to accelerate pediatric brain cancer treatment development.
NeOnc Technologies Holdings (NASDAQ: NTHI) has announced a strategic partnership with CBCC Global Research to expand its clinical trial network in India. The collaboration will establish 30 FDA-compliant research sites to accelerate patient enrollment for brain cancer treatments.
The primary focus is the NEO100-01 Glioblastoma (GBM) Phase 2a clinical trial, which evaluates the survival impact and tolerance of intranasal NEO100, an ultra-purified perillyl alcohol targeting IDH1 mutation in Grade 3 and 4 GBM tumors. The company aims to complete Phase 2 enrollment this year, with results expected 6-8 months afterward.
The trials will be conducted under Good Clinical Practices (GCP) and Good Laboratory Practices (GLP) standards, with CBCC coordinating with NeOnc's U.S.-based CRO, Anova Enterprises, to ensure streamlined operations.